At Seattle Cancer Care Alliance (SCCA), your care team will work with you to create an individualized treatment plan based on your specific diagnosis and preferences. Each patient is unique and therefore treatment plans will differ from patient to patient. We offer different treatment types, many with the option to participate in a clinical trial. We also offer treatment you may not be able to receive elsewhere such as certain types of cellular immunotherapy treatment.
Bone marrow transplantation is among the greatest success stories in cancer care. The Fred Hutch Bone Marrow Transplant Program at SCCA has led since the beginning, when Nobel Prize-winner E. Donnall Thomas, MD, and his team at Fred Hutch first developed clinical use of transplants in the 1970s.
Immunotherapy uses the power of your body’s own immune system to find and destroy tumors. SCCA physicians and researchers are leaders in discovering new ways to give your immune system the upper hand against cancer — making immunotherapy the science behind hope.
Treatments we offer
Patients receive medical oncology treatment from leading physicians who specialize in your cancer and are experts in their field. Medical oncology is the cancer treatment of using drugs, such as chemotherapy, to stop the progression of the disease.
Our radiation oncologists design individualized treatment plans to target your tumor and minimize the effects on healthy tissue. We offer several types of radiation therapy, including access to the latest and most innovative options through clinical studies.
Surgical oncology is the branch of surgery that specializes in treating cancer. UW Medicine surgeons, who perform surgery for SCCA patients, are all experts and many specialize in specific cancer operations.
An advanced form of radiation treatment, proton therapy can be calibrated with great precision to selectively kill cancer cells. Patients who require proton therapy are seen at the SCCA Proton Therapy Center.
A new diagnostic tool called UW-OncoPlex is making a positive difference in the treatments and outcomes of many SCCA patients. It tests a patient’s tumor tissue for the presence of characteristic genetic abnormalities called driver mutations.